Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Iloperidone · 1 trial · 1 indication
Pharmacokinetics of iloperidone in subjects with mild or moderate hepatic impairment, compared to healthy volunteers.
Blood and urine samples will be collected and plasma and urine concentration will be measured.
Blood samples will be collected and protein binding will be measured .
Blood and urine samples will be collected and plasma and urine concentration will be measured.
| Arm | Type | Description |
|---|---|---|
| Iloperidone | EXPERIMENTAL | Eligible subjects receive a single oral dose of 2 mg iloperidone as a tablet |
| Name | Type | Description |
|---|---|---|
| Iloperidone | DRUG | - |
Inclusion Criteria: * Inclusion criteria (all subjects): * Caucasian subjects * Inclusion criteria (hepatic impaired subjects): * subjects with physical signs consistent with a clinical diagnosis of stable liver disease, which has been confirmed by imaging techniques, ultrasound, Magnetic Resonance...
Iloperidone is a small molecule being studied for use in patients with hepatic impairment, specifically to evaluate its pharmacokinetics in mild or moderate liver disease. It is currently in Phase 1 clinical development as an investigational drug, and it is not approved for this condition.
Iloperidone is being developed by Novartis AG, which trades under the ticker symbol NVS. The company is conducting clinical research to assess the drug's behavior in patients with hepatic impairment.
Iloperidone is in Phase 1 clinical development for hepatic impairment. It is an investigational drug, meaning it has not been approved by regulatory authorities for this use and is still undergoing clinical trials to evaluate its safety and pharmacokinetics.
Iloperidone has one completed clinical trial, NCT01529294, titled 'Single-dose Iloperidone Pharmacokinetics in Patients With Mild or Moderate Liver Disease, Compared to Healthy Volunteers.' This Phase 1 study enrolled 90 participants in the United States and included healthy volunteers.
Iloperidone is also known by other names, though specific alternative names are not provided in the available information. It is a distinct small molecule being investigated for hepatic impairment.